RxDoctor Payments Data

Yolanda Thompson Martin

Adult Health · Kansas City, MONPI 1164694378

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Fresenius USA Marketing, Inc. accounts for 69.2% of it on its own, with 7 other manufacturers making up the rest. Among adult health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,853in general payments, 2019–2025

Across 70 payments — averaging $455.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$22K
  • Vifor Pharma, Inc.$9K
  • Amgen$218
  • Calliditas Therapeutics US Inc.$141
  • Bayer$107
  • AstraZeneca$98
  • plus $167 from 2 others

What the payments were for

  • Consulting fees$8,00025%
  • Speaking & faculty fees$13,16441%
  • Travel & lodging$8,13726%
  • Food & beverage$2,4748%
  • Education$790%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,853 in reported general payments places this provider in the 95th percentile of 555 adult health providers in Missouri.

See all adult health providers in Missouri

Medicare billing

Part B allowed, 2024
$2,447
Medicare patients
15
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide59$103,903
AuryxiaFerric Citrate24$32,424
VeltassaPatiromer Calcium Sorbitex22$24,277
FarxigaDapagliflozin Propanediol11$9,817
Sevelamer Carbonate46$6,014
Calcium Acetate34$2,023
Carvedilol92$773
Calcitriol28$488
Bumetanide11$480
Furosemide73$453
Atorvastatin Calcium41$429
Nifedipine ErNifedipine22$364
Losartan Potassium52$360
Allopurinol59$314
Midodrine Hcl17$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$22,054$103,90359 claims
Akebia Therapeutics IncAuryxia$88$32,42424 claims
AstraZenecaFarxiga$98$9,81711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 555 adult health providers in Missouri.

Other adult health in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →